3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Sarcoma
1
CNS
1
Conditions
Hodgkin Disease
4
Precursor Cell Lymphoblastic Leukemia-Lymphoma
3
Leukemia, Myeloid, Acute
3
Primary Myelofibrosis
2
Multiple Myeloma
2
Lymphoma, Non-Hodgkin
2
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
2
Leukemia, Lymphocytic, Chronic, B-Cell
2
Glioblastoma
2
Anemia, Refractory, with Excess of Blasts
2
Neoplasms, Plasma Cell
1
Neoplasms
1
Myelodysplastic Syndromes
1
Lymphoma, Mantle-Cell
1
Lymphoma, Extranodal NK-T-Cell
1
Hemoglobinuria, Paroxysmal
1
Hematologic Neoplasms
1
Gliosarcoma
1
Brain Neoplasms
1
Anemia, Aplastic
1
Interventions
Temozolomide
130
Radiotherapy
86
Bevacizumab
43
Radiation
31
Carmustine
29
Irinotecan
22
Erlotinib Hydrochloride
22
Magnetic Resonance Spectroscopy
21
Chemotherapy, Adjuvant
20
Surgical Procedures, Operative
15
O(6)-benzylguanine
15
Carboplatin
14
Radiotherapy, Intensity-Modulated
13
Radiotherapy, Conformal
13
sargramostim
12
Sirolimus
9
Imatinib Mesylate
9
Filgrastim
9
Drug Therapy
9
temsirolimus
8
Thalidomide
8
Sorafenib
8
Radiosurgery
8
pembrolizumab
7
motexafin gadolinium
7
aldesleukin
7
Vorinostat
7
Procarbazine
7
Gefitinib
7
Cyclophosphamide
7
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Interventional
×
Gliosarcoma
×
Basiliximab
×
Clear all
NCT00626483
2021-03-09
REGULATe
Duke University
Phase 1
Completed
34 enrolled